Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.66 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15394753 | 0.90 | THRB (0.73) | THRBRXFP1TRPA1TP53KMT2A | |
| SCHEMBL10114573 | 0.88 | THRB (0.76) | THRBRXFP1TRPA1TP53KMT2A | |
| SCHEMBL17527090 | 0.88 | RXFP1 (0.69) | THRBRXFP1TRPA1TP53KMT2A | |
| SCHEMBL10114003 | 0.87 | RXFP1 (0.76) | THRBRXFP1TRPA1TP53KMT2A | |
| SCHEMBL15394677 | 0.87 | THRB (0.68) | THRBRXFP1TRPA1TP53KMT2A | |
| SCHEMBL10114263 | 0.85 | RXFP1 (0.83) | THRBRXFP1TRPA1TP53KMT2A | |
| SCHEMBL20161686 | 0.84 | THRB (0.78) | THRBRXFP1TRPA1TP53KMT2A | |
| SCHEMBL10114748 | 0.84 | THRB (0.70) | THRBRXFP1TRPA1TP53KMT2A | |
| SCHEMBL10113830 | 0.84 | TRPA1 (0.77) | THRBRXFP1TRPA1TP53KMT2A | |
| SCHEMBL3826453 | 0.84 | TRPA1 (0.77) | THRBRXFP1TRPA1TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151248-A1 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | ELI LILLY AND COMPANY | 2017-06-01 | — | — | US | disclosed |
| US-9260430-B2 | Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents | HYDRA BIOSCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| WO-2010138879-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1 | HYDRA BIOSCIENCES, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151248-A1 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | TRPA1, TRPV1, TRPV2 | THRB 1103/4885RXFP1 396/4885TRPA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.